• Gilles Montalescot, Grégoire Rangé, Johanne Silvain, Jean-Louis Bonnet, Ziad Boueri, Olivier Barthélémy, Guillaume Cayla, Loic Belle, Eric Van Belle, Thomas Cuisset, Simon Elhadad, Christophe Pouillot, Patrick Henry, Pascal Motreff, Didier Carrié, Hélène Rousseau, Pierre Aubry, Jacques Monségu, Pierre Sabouret, Stephen A O'Connor, Jérémie Abtan, Mathieu Kerneis, Christophe Saint-Etienne, Farzin Beygui, Eric Vicaut, Jean-Philippe Collet, and ARCTIC Investigators.
• From the ACTION Study Group, Institut de Cardiologie (AP-HP), INSERM UMRS 1166, Université Paris 6, Paris, France (G.M., J.S., O.B., P.S., S.A.O., M.K., J.-P.C.); Hôpital Louis Pasteur, Le Coudray, France (G.R.); Hôpital de la Timone, Marseille, France (J.-L.B., T.C.); CH de Bastia, Bastia, France (Z.B.); CHU Carémeau, Nîmes, France (G.C.); CH de la Région Annecienne, Annecy, France (L.B.); Hôpital Cardiologique, Lille, France (E.V.B.); CH de Lagny, Marne-la-Vallée, France (S.E.); Clinique Sainte-Clothilde, La Réunion, France (C.P.); Hôpital Lariboisière, Paris, France (P.H.); CHU Clermont-Ferrand, Clermont-Ferrand, France (P.M.); Hôpital de Rangueil, Toulouse, France (D.C.); Unite de Recherche Clinique, Hôpital Lariboisière, ACTION Study Group, Paris, France (H.R., E.V.); Hôpital Bichat, Paris, France (P.A.); HIA du Val-du-Grâce, Paris, France (J.M.); Hôpital Bichat, ACTION Study Group, Paris, France (J.A.); Hôpital Trousseau, Chambray-lès-Tours, ACTION Study Group, Paris, France (C.S.-E.); and CHU Côte de Nacre, Caen, ACTION Study Group, Caen, France (F.B.). gilles.montalescot@psl.aphp.fr.
• Circulation. 2014 May 27;129(21):2136-43.

BackgroundIndividualizing antiplatelet therapy after platelet function testing did not improve outcome after coronary stenting in the Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting (ARCTIC) study. Whether results are different during the phase of secondary prevention starting after hospital discharge, when periprocedural events have been excluded, is unknown.Methods And ResultsIn ARCTIC, 2440 patients were randomized before coronary stenting to a strategy of platelet function monitoring (VerifyNow P2Y12/aspirin point-of-care assay) with drug adjustment in suboptimal responders to antiplatelet therapy or to a conventional strategy without monitoring and without drug or dose changes. We performed a landmark analysis starting at the time of hospital discharge evaluating the primary end point of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization through 1 year. After discharge, the primary end point occurred in 8.6% of patients in the monitoring arm and 7.9% in the conventional arm (hazard ratio, 1.105; 95% confidence interval, 0.835-1.461; P=0.48). Stent thrombosis or urgent revascularization occurred in 4.4% and 4.5% in the monitoring and conventional arms, respectively (P=0.99). There was no difference for any of the other ischemic end points. Major bleeding event rates were 1.8% in the monitoring arm and 2.8% in the conventional arm (P=0.11), whereas major or minor bleeding event rates were 2.3% and 3.4%, respectively (P=0.10).ConclusionsDetection of platelet hyper-reactivity by platelet function testing in patients undergoing coronary stenting with further therapeutic adjustment does not reduce ischemic recurrences after intervention. On-treatment platelet hyperreactivity cannot be considered as a risk factor requiring intervention for secondary prevention after percutaneous coronary revascularization.Clinical Trial Registration Urlhttp://www.clinicaltrials.gov. Unique identifier: NCT00827411.© 2014 American Heart Association, Inc.

25 keywords...

hide…